Back to Abbott

Abbott News

ABT

ABT: Abbott Plans Nutrition Spin-Off

Abbott (ABT) will separate its global nutrition unit into a standalone company. Key segment figures, risks and investor context as of 2026-10-21.

ABT

Abbott (ABT) to Acquire Exact Sciences — $20B Notes, Cash

Abbott (ABT) announces intent to acquire Exact Sciences on 2026-03-09, funded by $20B notes and cash. Analysis of funding, business segments, and risks.

ABT

Abbott (ABT) to Acquire Exact Sciences

Abbott (ABT) announces intent to acquire Exact Sciences, funded with $20B notes and cash. Analysis of financing, segment implications, governance and risks (2026-03-09).

ABT

Abbott Issues $20B Senior Notes to Fund Exact Sciences

Abbott (ABT) raises $20B through senior notes to finance its acquisition of Exact Sciences. Details, context, and investor implications as of 2026-03-09.

ABT

ABT: Abbott Labs Board Reduced to 12 (2026)

Abbott Laboratories (ABT) trims its board from 13 to 12 members, effective 2026. Key governance context and what investors should watch next.

ABT

Abbott (ABT) Adds Nita Ahuja to Board

Abbott Laboratories (ABT) appointed Nita Ahuja to its board, increasing the board to 13 members. Governance and investor implications for Abbott's strategic priorities.

ABT

ABT: Abbott Labs Increases Board to 13, Revises Governance

Abbott Labs (ABT) expands its board to 13 and updates shareholder governance. Investor-focused summary with context from Q3 2025 results and key risks.

ABT

Abbott Q3 & 9M 2025 Results — ABT Earnings

Abbott (ABT) posts double-digit EPS growth and higher sales in Q3 and nine months 2025; international revenue 61.2% of $32.9B nine-month sales.

ABT

Abbott Gains Key Approvals for Heart Devices

Abbott (ABT) secures regulatory and guideline endorsements for cardiac devices, reinforcing its Medical Devices segment; revenue and risk analysis for investors.